stockrowCompugen Ltd.
CGENCompugen Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $72.8 million, up 161.1% from fiscal 2024.
- Revenue
- +107.0%
- EPS
- +12.5%
- Free cash flow
- −155.4%
Quarter to June 2026, against a year earlier
Follow CGEN
Alert me
Compugen Ltd. (CGEN) Return on invested capital
Compugen Ltd.'s return on invested capital over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −1,022.3% (fiscal 2016) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 55.97 |
| FY2023 | −56.0% | (55.97) |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | 1,022.31 |
| FY2016 | −1,022.3% | (859.90) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| PRQR ProQR Therapeutics N.V. compare | 0.00% |
| CGEN Compugen Ltd. | 0.00% |
| RNA Atrium Therapeutics, Inc. compare | 0.00% |
| BBOT BridgeBio Oncology Therapeutics, Inc compare | −127.7% |
| ACOG Alpha Cognition Inc. compare | −144.7% |
| KROS Keros Therapeutics, Inc. compare | −233.2% |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | −279.8% |
| UPB Upstream Bio, Inc. compare | −1,100.9% |
| TRDA Entrada Therapeutics, Inc. compare | −2,009.0% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)